106
Participants
Start Date
November 9, 2018
Primary Completion Date
July 28, 2022
Study Completion Date
December 31, 2025
Durvalumab
1500mg by intravenous (IV) infusion on D1 until progression or unacceptable toxicity or withdrawal of consent
Tremelimumab
300mg by IV infusion on D1 at cycle 1 only
CHRU Jean Minjoz, Besançon
Polyclinique Bordeaux Nord Aquitaine, Bordeaux
Hôpital Duchenne, Boulogne-sur-Mer
CHU Morvan, Brest
Hôpital Beaujon, Clichy
CHPSO Site de Creil, Creil
CHU Henri Mondor, Créteil
Centre Georges François Leclerc, Dijon
CHU Dijon, Dijon
Institut Andrée Dutreix, Dunkirk
Institut Hospitalier franco-Britannique, Levallois-Perret
CHRU Lille, Lille
Centre Léon Bérard, Lyon
Hôpital Privé Jean Mermoz, Lyon
Hôpital la Timone, Marseille
Hôpital Saint Eloi, Montpellier
Hôpital Prive du confluent SAS, Nantes
Hôpital Cochin, Paris
Hôpital Saint Antoine, Paris
Institut Mutualiste Montsouris, Paris
Hôpital Haut Lévêque, Pessac
CHU Poitiers, Poitiers
CHU Robert Debré, Reims
Centre Eugène Marquis, Rennes
Institut Curie, Saint-Cloud
CHI Poissy Saint Germain, Saint-Germain-en-Laye
Centre Paul Strauss, Strasbourg
Insitut Gustave Roussy, Villejuif
Collaborators (1)
AstraZeneca
INDUSTRY
GERCOR - Multidisciplinary Oncology Cooperative Group
OTHER